Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
NEW YORK (
) -- The ex-dividend date for
) is Monday, October 29, 2012. Owners of shares as of market close today will be eligible for a dividend of 20 cents per share. At a price of $26.26 as of 9:30 a.m. ET, the dividend yield is 3.1%.
The average volume for Questcor has been 5.5 million shares per day over the past 30 days. Questcor has a market cap of $1.52 billion and is part of the health care sector and drugs industry. Shares are down 37.7% year to date as of the close of trading on Thursday.
Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. The company has a P/E ratio of 10, below the average drugs industry P/E ratio of 12.6 and below the S&P 500 P/E ratio of 17.7.
- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
TheStreet Ratings rates Questcor as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. You can view the full
FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge!
Free download now